XML 13 R2.htm IDEA: XBRL DOCUMENT v3.25.2
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
Jun. 30, 2025
Sep. 30, 2024
Current assets:    
Cash and cash equivalents $ 4,727,677 $ 5,852,363
Accounts receivable, net of allowance for credit losses of $80,423 and $75,000 at June 30, 2025 and September 30, 2024, respectively 199,047 328,252
Inventories 338,723 432,725
Prepaid expenses and other current assets 338,447 756,185
Current assets of discontinued operations 25,008 678,146
Total current assets 5,628,902 8,047,671
Property and equipment, net 511,203 458,895
Noncurrent assets of discontinued operations 11,264 94,337
Other assets:    
Restricted cash 750,000 750,000
Intangible assets 2,698,975 2,698,975
Operating right of use asset 334,402 739,162
Total assets 9,934,746 12,789,040
Current liabilities:    
Accounts payable and accrued liabilities 1,564,707 1,737,366
Operating lease liability, current 334,403 545,912
Deferred revenue 12,285 58,785
Current liabilities of discontinued operations 124,565 56,061
Total current liabilities 2,035,960 2,398,124
Long term accrued liabilities 31,467 31,467
Deferred revenue, long term 194,000 194,000
Operating lease liability, long term   193,249
Deferred tax liability, net 684,115 684,115
Warrants classified as a liability 1,160 320,000
Total liabilities 2,946,702 3,820,955
Commitments and contingencies (Note G)
Applied DNA Sciences, Inc. stockholders' equity:    
Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- shares issued and outstanding as of June 30, 2025 and September 30, 2024
Common stock, par value $0.001 per share; 200,000,000 shares authorized as of June 30, 2025 and September 30, 2024; 901,500 and 13,755 shares issued and outstanding as of June 30, 2025 and September 30, 2024, respectively 902 14
Additional paid in capital 381,150,267 318,815,358
Accumulated deficit (373,888,601) (309,672,755)
Applied DNA Sciences, Inc. stockholders' equity 7,262,568 9,142,617
Noncontrolling interest (274,524) (174,532)
Total equity 6,988,044 8,968,085
Total liabilities and equity 9,934,746 12,789,040
Series A Preferred stock    
Applied DNA Sciences, Inc. stockholders' equity:    
Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- shares issued and outstanding as of June 30, 2025 and September 30, 2024
Series B Preferred stock    
Applied DNA Sciences, Inc. stockholders' equity:    
Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- shares issued and outstanding as of June 30, 2025 and September 30, 2024